Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine.

Soares CN, Zhang M, Boucher M.

CNS Spectr. 2017 Nov 15:1-11. doi: 10.1017/S1092852917000633. [Epub ahead of print]

PMID:
29140227
2.

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.

Katzman MA, Nierenberg AA, Wajsbrot DB, Meier E, Prieto R, Pappadopulos E, Mackell J, Boucher M.

J Clin Psychopharmacol. 2017 Oct;37(5):555-561. doi: 10.1097/JCP.0000000000000775.

3.

Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.

Lam RW, Wajsbrot DB, Meier E, Pappadopulos E, Mackell JA, Boucher M.

J Psychopharmacol. 2017 Sep;31(9):1204-1214. doi: 10.1177/0269881117719261. Epub 2017 Jul 18.

PMID:
28718346
4.

Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study.

Watanabe K, Thase ME, Kikuchi T, Tsuboi T, Asami Y, Pappadopulos E, Zhang M, Boucher M, Kornstein S.

Int Clin Psychopharmacol. 2017 Sep;32(5):271-280. doi: 10.1097/YIC.0000000000000183.

PMID:
28598899
5.

Restoring function in major depressive disorder: A systematic review.

Sheehan DV, Nakagome K, Asami Y, Pappadopulos EA, Boucher M.

J Affect Disord. 2017 Jun;215:299-313. doi: 10.1016/j.jad.2017.02.029. Epub 2017 Feb 24. Review.

PMID:
28364701
6.

Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.

Mosca D, Zhang M, Prieto R, Boucher M.

J Clin Psychopharmacol. 2017 Apr;37(2):182-192. doi: 10.1097/JCP.0000000000000674.

PMID:
28146000
7.

A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.

Thase M, Asami Y, Wajsbrot D, Dorries K, Boucher M, Pappadopulos E.

Curr Med Res Opin. 2017 Feb;33(2):317-326. doi: 10.1080/03007995.2016.1255185. Epub 2016 Nov 28.

PMID:
27794623
8.

An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.

Carrasco JL, Kornstein SG, McIntyre RS, Fayyad R, Prieto R, Salas M, Mackell J, Boucher M.

Int Clin Psychopharmacol. 2016 May;31(3):134-46. doi: 10.1097/YIC.0000000000000121.

PMID:
26895080
9.

Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.

McIntyre RS, Fayyad R, Mackell JA, Boucher M.

Curr Med Res Opin. 2016;32(3):587-99. doi: 10.1185/03007995.2015.1136603. Epub 2016 Jan 13.

PMID:
26709542
10.

The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials.

Black D, Messig M, Yu CR, Assaf AR, Komm BS, Mirkin S, Boucher M.

Menopause. 2016 Apr;23(4):376-82. doi: 10.1097/GME.0000000000000541.

PMID:
26694733
11.

A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d.

McIntyre RS, Fayyad RS, Guico-Pabia CJ, Boucher M.

Prim Care Companion CNS Disord. 2015 Jun 4;17(3). doi: 10.4088/PCC.14m01741. eCollection 2015.

12.

Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis.

Clayton AH, Hwang E, Kornstein SG, Tourian KA, Cheng RF, Abraham L, Mele L, Boucher M.

Int Clin Psychopharmacol. 2015 Nov;30(6):307-15. doi: 10.1097/YIC.0000000000000094.

PMID:
26230270
13.

An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder.

McIntyre RS, Fayyad RS, Guico-Pabia CJ, Boucher M.

Prim Care Companion CNS Disord. 2015 Feb 26;17(1). doi: 10.4088/PCC.14m01681. eCollection 2015.

14.

Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.

Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA.

Curr Med Res Opin. 2015 Apr;31(4):809-20. doi: 10.1185/03007995.2015.1020365. Epub 2015 Mar 26.

PMID:
25758058
15.

Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.

Endicott J, Lam RW, Hsu MA, Fayyad R, Boucher M, Guico-Pabia CJ.

J Affect Disord. 2014 Sep;166:307-14. doi: 10.1016/j.jad.2014.05.011. Epub 2014 May 21.

PMID:
25012446
16.

Desvenlafaxine for the treatment of major depressive disorder.

Kornstein SG, McIntyre RS, Thase ME, Boucher M.

Expert Opin Pharmacother. 2014 Jul;15(10):1449-63. doi: 10.1517/14656566.2014.923403. Review.

PMID:
24914479
17.

Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine.

Lam RW, Endicott J, Hsu MA, Fayyad R, Guico-Pabia C, Boucher M.

Int Clin Psychopharmacol. 2014 Sep;29(5):239-51. doi: 10.1097/YIC.0000000000000031.

PMID:
24583567
18.

Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder.

Soares CN, Endicott J, Boucher M, Fayyad RS, Guico-Pabia CJ.

CNS Spectr. 2014 Dec;19(6):519-27. doi: 10.1017/S1092852914000066. Epub 2014 Feb 26.

PMID:
24571916
19.

Inhibition of Fas-associated death domain-containing protein (FADD) protects against myocardial ischemia/reperfusion injury in a heart failure mouse model.

Fan Q, Huang ZM, Boucher M, Shang X, Zuo L, Brinks H, Lau WB, Zhang J, Chuprun JK, Gao E.

PLoS One. 2013 Sep 13;8(9):e73537. doi: 10.1371/journal.pone.0073537. eCollection 2013.

20.

Cytosolic phospholipase A(2)α protects against ischemia/reperfusion injury in the heart.

Kerkelä R, Boucher M, Zaka R, Gao E, Harris D, Piuhola J, Song J, Serpi R, Woulfe KC, Cheung JY, O'Leary E, Bonventre JV, Force T.

Clin Transl Sci. 2011 Aug;4(4):236-42. doi: 10.1111/j.1752-8062.2011.00294.x.

Supplemental Content

Loading ...
Support Center